Claima6403777ad00251b19505c95c1e7cfbbae7f0819d6c88fe05fe5d2fee9e5ce8a·My Arguments

Across meta-analyses of GLP-1 receptor agonist trials, major adverse cardiovascular events are reduced by roughly 12–20% with concordant reductions in cardiovascular and all-cause mortality, and the cardiovascular benefit holds independently of diabetes status.

Evidence (1)

Cardiovascular outcomes of semaglutide and tirzepatide (2025)
Pooled GLP-1 RA evidence shows ~12-20% MACE reduction with mortality benefit, independent of diabetes status.
https://www.nature.com/articles/s41591-025-04102-x_reference.pdf

Respond to this claim on Isonomia

Build or challenge arguments with structured reasoning in the Digital Agora.

Join & respond

Embed this claim

<iframe
  src="https://www.isonomia.app/embed/claim/a6403777ad00251b19505c95c1e7cfbbae7f0819d6c88fe05fe5d2fee9e5ce8a"
  width="600"
  height="280"
  frameborder="0"
  style="border: 1px solid #e5e7eb; border-radius: 8px;"
  title="Isonomia Claim"
  loading="lazy"
></iframe>

Copy and paste into any website or forum that supports HTML.